Valneva (NASDAQ:VALN) Shares Up 4.9% – What’s Next?
by Renee Jackson · The Cerbat GemValneva SE Sponsored ADR (NASDAQ:VALN – Get Free Report)’s stock price shot up 4.9% during trading on Wednesday . The company traded as high as $8.78 and last traded at $8.7590. 33,647 shares were traded during trading, a decline of 45% from the average session volume of 60,685 shares. The stock had previously closed at $8.35.
Analyst Upgrades and Downgrades
Several research analysts have weighed in on VALN shares. Weiss Ratings restated a “sell (d-)” rating on shares of Valneva in a report on Wednesday, October 8th. Guggenheim reduced their price objective on Valneva from $14.00 to $13.00 and set a “buy” rating on the stock in a research note on Monday, September 8th. Finally, Wall Street Zen downgraded shares of Valneva from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $15.00.
Get Our Latest Stock Report on VALN
Valneva Trading Up 4.0%
The firm has a market capitalization of $747.87 million, a price-to-earnings ratio of -6.03 and a beta of 1.83. The business’s 50-day moving average price is $8.87 and its 200 day moving average price is $8.65. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.78 and a quick ratio of 1.36.
Valneva (NASDAQ:VALN – Get Free Report) last released its quarterly earnings results on Thursday, November 20th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.31). Valneva had a negative return on equity of 59.44% and a negative net margin of 57.81%.The firm had revenue of $34.01 million for the quarter, compared to analysts’ expectations of $48.85 million. On average, equities analysts forecast that Valneva SE Sponsored ADR will post 0.13 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in the stock. VSM Wealth Advisory LLC raised its stake in shares of Valneva by 125.0% in the 3rd quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock valued at $110,000 after purchasing an additional 5,000 shares in the last quarter. JPMorgan Chase & Co. bought a new stake in Valneva in the third quarter valued at about $124,000. Marex Group plc bought a new stake in Valneva in the second quarter valued at about $64,000. Finally, Frazier Life Sciences Management L.P. acquired a new stake in Valneva during the second quarter valued at approximately $8,240,000. 11.39% of the stock is owned by institutional investors and hedge funds.
About Valneva
Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.
Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.